| Project/Area Number |
24791773
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 癌幹細胞 / CD10 / 頭頸部扁平上皮癌 / 抗癌剤耐性 / 放射線耐性 / 細胞周期 / 抗体アレイ / 抗がん剤耐性 |
|---|
| Research Abstract |
Radiotherapy and chemotherapy initially control tumour growth in head and neck cancer. However, over time many patients suffer relapse. To improve prognosis, the establishment of a novel marker to predict therapeutic resistance is required. It is currently understood that cancer stem cells (CSCs) are responsible for treatment failure in a diversity of cancers. In the present study,sis and testing of cell viability in the presence of therapeutic agents, we identified CD10 as a potential marker of refractory HNSCC. Moreover, CD10 was found to confer a CSC-like phenotype, and underscored expression of OCT3/4. Thus, CD10 could be a specific marker of HNSCC CSCs that contributes to therapeutic resistance. These results were accepted by the British Journal of Cancer in 2014.
|
